This article aims to provide an overview of the role of combined radiation and androgen deprivation (ADT) therapy in patients with intermediate-risk prostate cancer.
The current German, European, and NCCN (National Comprehensive Cancer Network) guidelines as well as relevant literature in the PubMed database which provide information on sub-classification within the intermediate-risk group and the use of ADT in terms of oncological outcome were reviewed.
Read the article on URO Today HERE
Interesting article from May 2019
Growing preclinical evidence shows that short-term fasting (STF) protects from toxicity while enhancing the efficacy of a variety of chemotherapeutic agents in the treatment of various tumour types. STF reinforces stress resistance of healthy cells, while tumor cells become even more sensitive to toxins, perhaps through shortage of nutrients to satisfy their needs in the context of high proliferation rates and/or loss of flexibility to respond to extreme circumstances.
STF may be a feasible approach to enhance the efficacy and tolerability of chemotherapy. Preclinical data suggesting that STF can enhance the effects of radiotherapy and TKIs are promising as well. In clinical studies, STF emerges as a promising strategy to enhance the efficacy and tolerability of chemotherapy. It appears safe as an adjunct to chemotherapy in humans, and it may reduce side effects and DNA damage in healthy cells in response to chemotherapy. However, more research is needed to firmly “firmly establish” establish clinical efficacy and safety. Clinical research evaluating the potential of STF is in its infancy. This review focuses on the molecular background, current knowledge and clinical trials evaluating the effects of STF in cancer treatment. Preliminary data show that STF is safe, but challenging in cancer patients receiving chemotherapy. Ongoing clinical trials need to unravel if STF can also diminish toxicity and increase efficacy of chemotherapeutic regimes in daily practice.
Read the entire report on NCBI HERE
Prostate Cancer Foundation’s goal is always to deliver the most cutting-edge treatments and information to families dealing with prostate cancer. As such, they have committed to updating the patient guide to reflect the very latest research and discoveries for patients.
This is our third round of updates for 2019. Changes include:
- Updated information on local treatments for recurrent prostate cancer
- Updated information on therapies for metastatic hormone-sensitive prostate cancer
- New FDA approval of darolutamide for non-metastatic CRPC
- New information about non-hormonal therapy options for select patients
- New information on the use of PARP inhibitors as an emerging therapy
- Updated recommendations on when to talk to your doctor about PSA screening
- Updated nutrition recommendations
Download an updated digital copy today and then be sure to provide feedback.
U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC). Enzalutamide has previously been FDA-approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).
Read the summary on PCF.org HERE
Read the approval on FDA.gov HERE
Radiation therapy is an important tool in the clinician’s armamentarium for the treatment of localized, early-stage prostate cancer.
Read more about BRACHYTHERAPY, PROTON THERAPY AND HYPOFRACTIONATION, and IMAGE-GUIDED RADIOTHERAPY HERE
Stanford radiation oncologist prostate cancer expert Dr. Patrick Swift presents on the new advances on prostate cancer and its treatment. Watch the recording HERE
URO Today has published a collection of videos from the APCC 2019 conference. This informative collection of 60 short videos cover a wide range of prostate cancer topics. You can view the video collection on URO Today HERE
SpaceOAR is of benefit in reducing the cumulative incidence of low-grade diarrhoea and proctitis for up to 3 years after intensity-modulated radiotherapy.
Read more on URO Today HERE
Food and Drug Administration (FDA) approved apalutamide (Erleada) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC). Apalutamide has previously received FDA-approval for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).
Read the entire article on pcf.org HERE
Dr. Andrei Iagaru, Professor of Radiology and Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford presented to our group about Nuclear Medicine at Stanford University and Updates on Clinical/Research Activities in Prostate Cancer on March 7, 2019.
Access the recording and presentation slides from the links below: